132 related articles for article (PubMed ID: 36346180)
1. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer.
Li M; Liao K; Chen AJ; Cascone T; Shen Y; Lu Q; Shih YT
J Natl Cancer Inst; 2023 Mar; 115(3):295-302. PubMed ID: 36346180
[TBL] [Abstract][Full Text] [Related]
2. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.
Li M; Liao K; Nowakowska M; Wehner M; Shih YT
J Manag Care Spec Pharm; 2023 Nov; 29(11):1232-1241. PubMed ID: 37889870
[No Abstract] [Full Text] [Related]
3. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
5. Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.
Kehl KL; Lathan CS; Johnson BE; Schrag D
J Natl Cancer Inst; 2019 Apr; 111(4):431-434. PubMed ID: 30576459
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
Bishnoi R; Shah C; Blaes A; Bian J; Hong YR
Lung Cancer; 2020 Dec; 150():172-177. PubMed ID: 33186859
[TBL] [Abstract][Full Text] [Related]
7. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer.
Leapman MS; Dinan M; Pasha S; Long J; Washington SL; Ma X; Gross CP
JAMA Oncol; 2022 May; 8(5):687-696. PubMed ID: 35238879
[TBL] [Abstract][Full Text] [Related]
8. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
Wang CY; Heldermon CD; Vouri SM; Park H; Wheeler SE; Ramnaraign BH; Dang NH; Brown JD
JAMA Netw Open; 2021 Nov; 4(11):e2133474. PubMed ID: 34812849
[TBL] [Abstract][Full Text] [Related]
9. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
10. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
11. Hepatopancreaticobiliary cancer outcomes are associated with county-level duration of poverty.
Lima HA; Woldesenbet S; Hamad A; Alaimo L; Moazzam Z; Endo Y; Shaikh C; Azap LE; Munir MM; Resende V; Pawlik TM
Surgery; 2023 Jun; 173(6):1411-1418. PubMed ID: 36774319
[TBL] [Abstract][Full Text] [Related]
12. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers.
Cheng E; Soulos PR; Irwin ML; Cespedes Feliciano EM; Presley CJ; Fuchs CS; Meyerhardt JA; Gross CP
JAMA Netw Open; 2021 Dec; 4(12):e2139593. PubMed ID: 34919133
[TBL] [Abstract][Full Text] [Related]
13. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
14. Association of Area-Level Socioeconomic Deprivation With Hypoglycemic and Hyperglycemic Crises in US Adults With Diabetes.
Kurani SS; Heien HC; Sangaralingham LR; Inselman JW; Shah ND; Golden SH; McCoy RG
JAMA Netw Open; 2022 Jan; 5(1):e2143597. PubMed ID: 35040969
[TBL] [Abstract][Full Text] [Related]
15. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B
J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551
[TBL] [Abstract][Full Text] [Related]
17. Use of a Novel Network-Based Linchpin Score to Characterize Accessibility to the Oncology Physician Workforce in the United States.
Moen EL; Brooks GA; O'Malley AJ; Schaefer A; Carlos HA; Onega T
JAMA Netw Open; 2022 Dec; 5(12):e2245995. PubMed ID: 36525275
[TBL] [Abstract][Full Text] [Related]
18. Impact of Area Deprivation Index on Coronary Stent Utilization in a Medicare Nationwide Cohort.
Tuliani TA; Shenoy M; Parikh M; Jutzy K; Hilliard A
Popul Health Manag; 2017 Aug; 20(4):329-334. PubMed ID: 28106520
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
20. Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies.
Tomicki S; Dieguez G; Latimer H; Cockrum P; Kim G
Am Health Drug Benefits; 2021 Jun; 14(2):70-78. PubMed ID: 34267862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
